On October 22, patients, physicians, and other interested parties will have the opportunity to provide input on the value and cost of mavacamten – the first drug specifically designed to treat hypertrophic cardiomyopathy.

(...more)

Originally published as What Should Mavacamten Cost? at HCM Beat

Subscription RSS Feed: https://hcmbeat.com/feed/

Disability News Wire Enters Open Beta Testing

2021-03-08

Disability News Wire has entered beta testing with an early release of its Internet wire service for the Disability Community. Our goal is to bring…

more

Keep up with podcasts like this

If you find resources like this helpful, consider subscribing to our newsletter so you can have the latest news, analyses, podcasts, and videos mailed to you.


We'd really like to hear what you think about any of the podcasts we share here, our site, or anything we can do to be more useful for you. Thank you!